

**Tabrecta™ (Capmatinib) Prior Authorization Form**

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

**Drug Information**

Pharmacy Billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

**Billing Provider Information**

Pharmacy NPI: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_

Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_

**Prescriber Information**

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

**Criteria****For Initial Authorization:****1. Please indicate the diagnosis and information:** **Non-Small Cell Lung Cancer (NSCLC)**A. Is diagnosis recurrent, advanced, or metastatic NSCLC? Yes  No B. Is tumor positive for mesenchymal-epithelial transition (MET) exon 14 skipping?  
Yes  No C. Will capmatinib be used as a single-agent? Yes  No  **If answer is none of the above, please indicate diagnosis:** \_\_\_\_\_

Additional Information: \_\_\_\_\_

**For Continued Authorization:**

1. Date of last dose: \_\_\_\_\_

2. Does member have any evidence of progressive disease while on capmatinib? Yes  No 3. Has the member experienced adverse drug reactions related to capmatinib therapy? Yes  No 

If yes, please specify adverse reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.***Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to  
**888-601-8461** or submit Electronic Prior Authorization  
through CoverMyMeds® or SureScripts.  
All requested data must be provided. Incomplete forms or  
forms without the chart notes will be returned. Pharmacy  
Coverage Guidelines are available at  
**AetnaBetterHealth.com/Oklahoma.**

**CONFIDENTIALITY NOTICE**

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*